How to cite item

VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?

   
@article{ATM22438,
	author = {Mariam Alexander and Balazs Halmos},
	title = {VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?},
	journal = {Annals of Translational Medicine},
	volume = {6},
	number = {23},
	year = {2018},
	keywords = {},
	abstract = {Over the last 15 years, multiple generations of EGFR tyrosine kinase inhibitors (TKIs) have completely transformed the landscape of management of EGFR-mutated lung cancers but are rarely used in other settings. In the pre-molecular testing era, the 1st generation reversible EGFR inhibitor, erlotinib, was shown to prolong survival in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of first- or second-line chemotherapy compared to placebo [overall survival (OS) was 6.7 vs. 4.7 months, hazard ratio (HR) 0.70, P},
	issn = {2305-5847},	url = {https://atm.amegroups.org/article/view/22438}
}